Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.57 |
| ▸ | CTSK | P43235 | 6/20 | 0.54 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.53 |
| ▸ | CAPN2 | P17655 | 1/20 | 0.53 |
| ▸ | TPSAB1 | Q15661 | 2/20 | 0.53 |
| ▸ | PLG | P00747 | 1/20 | 0.53 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.53 |
| ▸ | CTSS | P25774 | 4/20 | 0.50 |
| ▸ | CTSL | P07711 | 3/20 | 0.50 |
| ▸ | HTT | P42858 | 1/20 | 0.50 |
| ▸ | CTSB | P07858 | 2/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9136357 | 0.88 | CTSK (0.62) | CYP1A2CTSKTPSAB1PLGPRSS1 | |
| SCHEMBL12294550 | 0.88 | CYP2D6 (0.62) | CYP1A2CTSKCAPN1CAPN2TPSAB1 | |
| SCHEMBL20542838 | 0.85 | SIRT2 (0.60) | — | |
| SCHEMBL20542840 | 0.85 | SIRT2 (0.60) | — | |
| SCHEMBL10481494 | 0.85 | SIRT2 (0.60) | — | |
| SCHEMBL8502694 | 0.85 | CYP1A2 (0.58) | CYP1A2CTSKTPSAB1PLGPRSS1 | |
| SCHEMBL11702018 | 0.85 | CYP1A2 (0.58) | CYP1A2CTSKCAPN1CAPN2TPSAB1 | |
| SCHEMBL10957418 | 0.85 | CYP1A2 (0.58) | CYP1A2CTSKCAPN1CAPN2TPSAB1 | |
| SCHEMBL15318479 | 0.85 | CA5A (0.62) | CYP1A2CTSKTPSAB1PLGPRSS1 | |
| SCHEMBL10954836 | 0.85 | CA5A (0.62) | CYP1A2CTSKTPSAB1PLGPRSS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8119653-B2 | Belactosin derivatives as therapeutic agents/biological probes and their synthesis | THE TEXAS A&M UNIVERSITY SYSTEM (US) | 2012-02-21 | — | — | US | disclosed |
| US-20090042922-A1 | NOVEL BELACTOSIN DERIVATIVES AS THERAPEUTIC AGENTS/BIOLOGICAL PROBES AND THEIR SYNTHESIS | NATIONAL SCIENCE FOUNDATION | 2009-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090042922-A1 | NOVEL BELACTOSIN DERIVATIVES AS THERAPEUTIC AGENTS/BIOLOGICAL PROBES AND THEIR SYNTHESIS | PSMB1, PSMB10, PBK | CYP1A2 3211/4885CTSK 98/4885CAPN1 2239/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.